Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Precancerous Conditions 26Neoplasms 8Obesity-Related Malignant Neoplasm 7Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Leukemia 5Uterine Cervical Neoplasms 4Preleukemia 4Neoplasms by Histologic Type 4Hematologic Diseases 4Bone Marrow Diseases 4Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Biphenotypic, Acute 3Keratosis, Actinic 3Immunoproliferative Disorders 3Immune System Diseases 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Advanced Malignant Neoplasm 3Uterine Cervical Dysplasia 2Thrombocythemia, Essential 2Stomach Neoplasms 2Skin Diseases 2Neoplasms by Site 2Myelodysplastic-Myeloproliferative Diseases 2

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Stem Cell Transplantation 1Sirolimus 1Mycophenolic Acid 1Hematopoietic Stem Cell Transplantation 1Cyclophosphamide 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non-Malignant Neoplasm × Other neoplasm × 1 year × Clear all
NCT04083183 2025-12-18

Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Other neoplasm

Non-Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡